๐Ÿฅ VAERS Vaccine Data Browser

๐Ÿ”’ Privacy & Data Disclaimer

About This Site

This is a public data browser for the Vaccine Adverse Event Reporting System (VAERS). By using this site, you acknowledge and agree to the following:

Data Source & Accuracy

  • Public Data: All data displayed comes from the publicly available VAERS database maintained by the CDC and FDA.
  • No Verification: VAERS accepts all reports without verifying medical accuracy. Reports do not prove causation between vaccines and adverse events.
  • Anyone Can Report: Healthcare providers, patients, family members, and anyone else can submit reports to VAERS.
  • Research Purpose: This data is for transparency, research, and monitoring vaccine safety signals only.

Your Privacy

  • No Personal Data Collection: This site does not collect, store, or track any personal information about visitors.
  • No Cookies: We do not use cookies except for remembering that you've seen this disclaimer (stored locally in your browser).
  • No Analytics: We do not use Google Analytics or any other tracking services.
  • Search Privacy: Your searches and filters are not logged or stored on our servers.
  • Public Data Only: The VAERS data shown here is already public and contains no personally identifiable information.

Medical Disclaimer

  • Not Medical Advice: This tool is for informational purposes only and does not provide medical advice.
  • Consult Healthcare Providers: Always consult qualified healthcare professionals for medical decisions.
  • No Liability: We are not responsible for decisions made based on this data.

Data Interpretation

  • The presence of a report does not mean the vaccine caused the adverse event.
  • Coincidental events are often reported (e.g., a heart attack that happened to occur after vaccination).
  • Serious adverse events must be reported by law, even if unrelated to the vaccine.
  • The database is useful for detecting safety signals that require further investigation.

๐Ÿ“– Help & Search Guide

Column Icons Legend

๐Ÿ’€ Death
๐Ÿฅ Hospitalized
๐Ÿš‘ Emergency Room
โ™ฟ Disability
โš ๏ธ Life Threatening

How to Search

๐Ÿ’ก Search Tips:
  • Select Year: Choose a specific year OR "All Years" to search across all data
  • All Years requires filters: When searching all years, you must select at least one filter (lot number, vaccine type, outcome, etc.) for performance
  • Lot number tracking: Use "All Years" + Lot Number to track lots across multiple years
  • Combine filters: Use multiple filters together to narrow results (e.g., Age + Vaccine Type + Death)
  • VAERS ID: Search for specific report by ID number
  • Age: Enter exact age (e.g., 25) or decimal (e.g., 0.5 for 6 months)
  • State: Enter 2-letter state code (e.g., CA, NY, TX)
  • Vaccine Type: Search partial names (e.g., "COVID19", "FLU", "HPV")
  • Manufacturer: Search by company (e.g., "PFIZER", "MODERNA")
  • Lot Number: Search specific vaccine lot (works great with "All Years")
  • Symptoms: Search for any symptom keyword (e.g., "fever", "rash")
  • Death/Hospitalized: Filter to only show cases with these outcomes

Understanding the Data

  • Reports are unverified: VAERS accepts all reports without medical verification
  • Not proof of causation: A report does not mean the vaccine caused the event
  • Anyone can report: Healthcare providers, patients, and family members can submit reports
  • Multiple vaccines: One report may list multiple vaccines given at the same time
  • Blank fields: Not all fields are required, so some data may be missing

Using the Table

  • Sort columns: Click column headers (ID, Age, Sex, Date, Died) to sort
  • Expand text: Click "More" to see full narrative or symptom text
  • Navigate pages: Use pagination controls at top and bottom of table
  • Export results: Click "๐Ÿ“ฅ Export CSV" to download filtered data (max 10,000 records)

๐Ÿ’ก Frequently Asked Questions (FAQ)

What is this site?

๐Ÿฅ VAERS Vaccine Data Browser is an independent, third-party data browser for publicly available VAERS (Vaccine Adverse Event Reporting System) data.

Important: This site is NOT affiliated with, endorsed by, or operated by the CDC, FDA, or any government agency. We are an independent service that makes public VAERS data easier to search and analyze.

What is VAERS?

VAERS (Vaccine Adverse Event Reporting System) is a national early warning system established in 1990 to detect possible safety problems with vaccines. It's co-managed by the CDC (Centers for Disease Control and Prevention) and FDA (Food and Drug Administration).

VAERS accepts and analyzes reports of adverse events (possible side effects) after a person has received a vaccination.

Official VAERS website: vaers.hhs.gov

Is this data HIPAA compliant?

Yes, absolutely. All VAERS data displayed here is:

  • Publicly available - Published by the CDC/FDA on their official website
  • De-identified - Contains no personally identifiable information (names, addresses, contact info removed)
  • Legally accessible - Available to researchers, media, and the general public under FOIA (Freedom of Information Act)
  • Not protected health information - Once de-identified and published by the government, it's no longer covered by HIPAA restrictions

This site displays the same public data available at vaers.hhs.gov/data.

Why does this site exist?

We believe in transparency and public access to health data. While the CDC/FDA provide VAERS data, their official site:

  • Is difficult to search and filter
  • Requires downloading large CSV files and technical knowledge
  • Is not user-friendly for the average person

This independent site makes the same publicly available data easier to search, filter, and understand for researchers, journalists, healthcare workers, and concerned citizens.

Where does the data come from?

All data is downloaded directly from the official CDC/FDA VAERS website at vaers.hhs.gov/data.

The data is:

  • Publicly released by the CDC/FDA every week
  • Available as downloadable CSV files
  • Imported into this site's database for easier searching
  • Displayed exactly as provided (no modifications or filtering)

This site does not collect, modify, or add to the official VAERS data.

My vaccine lot number matches one with deaths/serious events - should I be worried?

Important context:

  • VAERS reports do NOT prove causation - A report means an event occurred after vaccination, but doesn't mean the vaccine caused it
  • Anyone can report - Reports are not verified for medical accuracy before being published
  • Coincidences happen - When millions of people get vaccinated, some will experience unrelated medical events afterward
  • Large lot numbers - Popular vaccines may have hundreds of thousands of doses from one lot number
  • More vaccinations = more reports - Lots used widely will naturally have more reports

What to do:

  • Don't panic - VAERS data requires expert analysis to interpret
  • Talk to your doctor if you have concerns
  • Check official CDC/FDA safety communications for genuine safety signals
  • Remember: billions of vaccine doses have been safely administered

Can I trust VAERS data?

VAERS is valuable but has limitations:

Strengths:

  • โœ… Early warning system for potential safety signals
  • โœ… Open and transparent - publicly accessible
  • โœ… Accepts all reports regardless of likelihood of causation
  • โœ… Monitored by CDC/FDA experts who investigate concerning patterns

Limitations:

  • โš ๏ธ Reports are unverified - not investigated before publication
  • โš ๏ธ Cannot determine if vaccine caused the event
  • โš ๏ธ Underreporting - not all adverse events are reported
  • โš ๏ธ Overreporting - coincidental events may be reported
  • โš ๏ธ Incomplete data - not all fields are required

Bottom line: VAERS is an important tool for safety monitoring, but individual reports should not be used as proof that a vaccine caused harm.

What are "adverse events"?

An adverse event is any undesirable health occurrence that happens after vaccination, including:

  • Common reactions: Sore arm, mild fever, fatigue (usually expected)
  • Serious events: Hospitalization, disability, life-threatening illness, death
  • Coincidental events: Medical conditions that would have occurred anyway

Important: An adverse event doesn't mean the vaccine caused it - only that it occurred after vaccination. Many reported events are coincidental or unrelated.

Why are some lot numbers listed multiple times?

This is normal and expected! A person may receive multiple doses of the same vaccine from the same lot number:

  • COVID vaccines require 2-3 doses
  • HPV, Hepatitis B, and other vaccines have multi-dose schedules
  • Each dose is recorded as a separate entry

Example: Person receives Pfizer COVID dose 1 (lot ABC123) and dose 2 (lot ABC123) - lot ABC123 appears twice in their report.

How often is this data updated?

The CDC/FDA releases new VAERS data every Friday. This site is typically updated:

  • Weekly or bi-weekly for recent data
  • Check the available years to see what data is currently loaded
  • During updates, the site may be in maintenance mode temporarily

Where can I learn more?

โš ๏ธ DISCLAIMER: This data is from the Vaccine Adverse Event Reporting System (VAERS). Reports do not establish causation between vaccines and adverse events. Anyone can submit a report, and reports are not verified. This is raw data for transparency and research purposes only.
34,052
Total Reports (2025)
500
Deaths Reported
1,634
Hospitalizations
30
ER Visits
1,191
Disabilities
570
Life Threatening
๐Ÿ”„ Reset ๐Ÿ“ฅ Export CSV
ID Age Sex State Date โ–ผ Onset Days Vaccine Manufacturer Lot # Symptoms Narrative ๐Ÿ’€ ๐Ÿฅ ๐Ÿš‘ โ™ฟ โš ๏ธ
2828879 1 F OK 02/28/2025 DTAPIPV
 GLAXOSMITHKLINE BIOLOGICALS
 3RT93
Inappropriate schedule of product administration, Product administered to patien... Inappropriate schedule of product administration, Product administered to patient of inappropriate age, Wrong product administered More
patient was supposed to receive a hepatitis A vaccine, but was inadvertently administered a dose of ... patient was supposed to receive a hepatitis A vaccine, but was inadvertently administered a dose of Kinrix instead; 12 month old female patient received kinrix; The Kinrix made the patient's fourth DTaP; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a 12-month-old female patient who received DTPa-IPV (Kinrix) (batch number 3RT93, expiry date 03-APR-2026) for prophylaxis. Co-suspect products included Hepatitis A vaccine for prophylaxis. On 31-JAN-2025, the patient received Kinrix. On an unknown date, the patient did not receive Hepatitis A vaccine. On 31-JAN-2025, immediately after receiving Kinrix and not applicable after receiving Hepatitis A vaccine, the patient experienced wrong vaccine administered (Verbatim: patient was supposed to receive a hepatitis A vaccine, but was inadvertently administered a dose of Kinrix instead), inappropriate age at vaccine administration (Verbatim: 12 month old female patient received kinrix) and inappropriate schedule of vaccine administered (Verbatim: The Kinrix made the patient's fourth DTaP). The outcome of the wrong vaccine administered, inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 31-JAN-2025 The reporter reported that a 12 month old female patient had been supposed to receive a hepatitis A vaccine, but was inadvertently administered a dose of Kinrix instead on 31st January 2025, which led to wrong vaccine administered and inappropriate age at vaccine administration. The Kinrix had made the patient's fourth DTaP and IPV dose, with most recent prior dose in August 2024, which led to inappropriate schedule of vaccine administered. The patient had been due for 15 month old DTaP in April 2025. The Kinrix dose had been administered from lot number 3RT93 and expiration date 03th April 2026. The patient had left with plans to come back another day to receive the hepatitis A dose. More
2828880 M WV 02/28/2025 TDAP
 GLAXOSMITHKLINE BIOLOGICALS
 CX4HL
Extra dose administered Extra dose administered
A twelve year old patient received a first dose of BOOSTRIX on August eight twenty-twenty four and a... A twelve year old patient received a first dose of BOOSTRIX on August eight twenty-twenty four and a second dose today; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 12-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number CX4HL, expiry date 09-NOV-2026) for prophylaxis. Previously administered products included Boostrix (received 1st dose on 08-AUG-2024). On 11-FEB-2025, the patient received the 2nd dose of Boostrix. On 11-FEB-2025, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: A twelve year old patient received a first dose of BOOSTRIX on August eight twenty-twenty four and a second dose today). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-FEB-2025 The reporter gave a Boostrix vaccine that was not needed. A patient received a first dose of Boostrix and received second dose on the day of reporting which led to extra dose administered. Licensed practice nurse inquired about any advice on this situation. Vaccination date, vaccine detail and patient demographics were obtained in this call. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter. More
2828881 60 M FL 02/28/2025 MENB
 NOVARTIS VACCINES AND DIAGNOSTICS
 3L339
Product administered to patient of inappropriate age Product administered to patient of inappropriate age
administer to 60 year old patient"; This non-serious case was reported by a pharmacist via call... administer to 60 year old patient"; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 60-year-old male patient who received Men B NVS (Bexsero) (batch number 3L339, expiry date 03-SEP-2027) for prophylaxis. On 11-FEB-2025, the patient received the 1st dose of Bexsero. On 11-FEB-2025, an unknown time after receiving Bexsero, the patient experienced inappropriate age at vaccine administration (Verbatim: administer to 60 year old patient"). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-FEB-2025 The reporter reported that there was a vaccine, the Bexsero vaccine that it was administered at our pharmacy on 11th February 2025, it said that the ages was between 10 to 25 years of age for administration, and the pharmacist that worked that day did not see that and administer to 60 year old patient. The Vaccine Administration Facility was the same as Primary Reporter. The healthcare professional mentioned that this was the 1st Bexsero dose that the patient received which led to inappropriate age at vaccine administration. More
2828882 CT 02/28/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Inappropriate schedule of product administration Inappropriate schedule of product administration
Inappropriate Schedule of Vaccine; This non-serious case was reported by a pharmacist via call cente... Inappropriate Schedule of Vaccine; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine 2 years ago). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Inappropriate Schedule of Vaccine). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 19-FEB-2025 The reporter asked that if a person who dosed their first dose of Shingrix more than 2 years ago, what would be the anticipated percentage of coverage for, so they dosed their first dose more than 2 years ago and want another dose now. Do they need to restart altogether or do they have 80% coverage, 60% coverage. If you could please give me a call back, I would greatly appreciate it. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. More
2828883 52 F FL 02/28/2025 HEPAB
 GLAXOSMITHKLINE BIOLOGICALS
Inappropriate schedule of product administration Inappropriate schedule of product administration
Twinrix late third dose; Twinrix late second dose; This non-serious case was reported by a pharmacis... Twinrix late third dose; Twinrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 52-year-old female patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. On 20-FEB-2025, the patient received the 3rd dose of Twinrix. On 19-FEB-2025, the patient received the 2nd dose of Twinrix. On 19-FEB-2025, not applicable after receiving Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix late second dose). On 20-FEB-2025, the patient experienced drug dose administration interval too short (Verbatim: Twinrix late third dose). The outcome of the drug dose administration interval too short and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 20-FEB-2025 Other HCP reported that she could give a third dose of Twinrix to a patient who received the second dose on 19th February 2025 and the first dose six months ago. Third dose has not been given. Patient received 2nd dose of Twinrix,?later than the recommended interval, which led to lengthening of vaccinations schedule. (Drug dose administration interval too long) Patient received 3rd dose of Twinrix,?earlier than the recommended interval, which led to shortening of vaccinations schedule. (Drug dose administration interval too short) More
2828884 F FL 02/28/2025 COVID19
 JANSSEN
COVID-19, Drug ineffective COVID-19, Drug ineffective
Covid; lack of effect; This spontaneous report received from a consumer concerned a female patient o... Covid; lack of effect; This spontaneous report received from a consumer concerned a female patient of unspecified age. The patient's height and weight were not reported. Age at time of vaccination was unknown. The patient's concurrent conditions included: non smoker. The patient was previously treated with janssen covid-19 vaccine for covid-19 prophylaxis. (dose series 1) The patient received janssen covid-19 vaccine (suspension for injection, intramuscular, batch number not reported) dose, frequency and therapy dates not reported, additional dosage information included: dose series 2, for covid-19 prophylaxis. 0.50 mL. Batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced covid and lack of effect. (dose series 2). It was reported that the Johnson and Johnson vaccines were of the poorest quality and they did not work. Patient had her second vaccine with Johnson and Johnson 2 years ago before Christmas or 3 years ago in November and in January, she died of COVID. And she was perfectly healthy. She had no problems. She didn't have any diabetes, cancer, or what have you. And she was a nonsmoker, and she died of it. The action taken with janssen covid-19 vaccine was not applicable. It was unknown if an autopsy was performed. Reported cause of death was covid. The patient died of covid on an unspecified date. The outcome of lack of effect was not reported. This report was associated with a product quality complaint: Product Complaint 90000353174. Investigation Results: 90000353174:Void:N:Product identification information and/or physical evidence, including field sample or photograph to conduct a root cause investigation was not available at the time of this assessment. Root cause and disposition determinations were assessed based on available information.. This report was serious (death and other medically important condition).; Sender's Comments: V0: COVID-19: The events have an unknown/unclear temporal relationship, are unlabeled, and have unknown scientific plausibility. There are other factors more likely to be associated with the events than the drug. Specifically: NATURE OF THE EVENT . Therefore, these events are considered not related. Drug ineffective: The event is a special reporting situation and owing to its own nature, it is not possible to attribute this occurrence to the suspect drug. Hence, the causality is considered as not related.; Reported Cause(s) of Death: Covid More
โœ“
2828885 F 02/28/2025 COVID19
 MODERNA
COVID-19, Pain, Vaccination failure COVID-19, Pain, Vaccination failure
pain and suffering; has the COVID virus for 3 times; Moderna sold a product that doesn't work; ... pain and suffering; has the COVID virus for 3 times; Moderna sold a product that doesn't work; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PAIN (pain and suffering), COVID-19 (has the COVID virus for 3 times) and VACCINATION FAILURE (Moderna sold a product that doesn't work) in a female patient of an unknown age who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. No Medical History information was reported. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN (pain and suffering), COVID-19 (has the COVID virus for 3 times) and VACCINATION FAILURE (Moderna sold a product that doesn't work). At the time of the report, PAIN (pain and suffering), COVID-19 (has the COVID virus for 3 times) and VACCINATION FAILURE (Moderna sold a product that doesn't work) outcome was unknown. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Unknown) was unknown. No concomitant medication was reported. The patient had the COVID virus for 3 times since having the Moderna vaccine. She experienced pain and suffering. Moderna sold a product that doesn't work. Investigation Summary & Conclusion with Root Cause Details: On 19FEB2025, a consumer contacted Moderna regarding concerns about the effectiveness of the Spikevax (COVID-19 Vaccine, mRNA). The caller reported that his wife had contracted COVID-19 three times despite receiving the Moderna vaccine, questioning its efficacy. The individual alleged that the vaccine was not properly tested and claimed that it did not prevent COVID-19 as expected. However, no specific product details, such as batch numbers or administration history, were provided, and the caller declined consent for follow-up. The case was forwarded to the Drug Safety team for adverse event reporting, and the regulatory product disclosure was provided. Given that no batch information or additional details were made available, further investigation into the perceived lack of effectiveness was not feasible. It is important to note that while Spikevax is indicated for the prevention of COVID-19, breakthrough infections can still occur due to various factors, including individual immune response and circulating virus variants. No treatment medication was reported. Reporter causality was not reported. Reporter did not allow further contact Most recent FOLLOW-UP information incorporated above includes: On 19-Feb-2025: Live non-significant information received: reference number added. On 21-Feb-2025: Live significant information received: Closed PQC report received, QC comment and narrative updated. More
2828886 68 F 02/28/2025 COVID19
COVID19
 MODERNA
MODERNA

COVID-19, Chest pain, Ear pain, Malaise, SARS-CoV-2 test; Taste disorder COVID-19, Chest pain, Ear pain, Malaise, SARS-CoV-2 test; Taste disorder
tested positive with Covid (home test) on 12FEB2025; Awful taste in the mouth; still feel unwell; ea... tested positive with Covid (home test) on 12FEB2025; Awful taste in the mouth; still feel unwell; ears hurt; chest hurts; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (tested positive with Covid (home test) on 12FEB2025), TASTE DISORDER (Awful taste in the mouth), MALAISE (still feel unwell), EAR PAIN (ears hurt) and CHEST PAIN (chest hurts) in a 68-year-old female patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis. The patient's past medical history included Ex-smoker (Smoked for 30 years, quit 15 years ago). Previously administered products included for Product used for unknown indication: Covid-19 vaccine (Dose 7) on 21-Nov-2023, Covid-19 vaccine (Dose 8) on 13-May-2024 and Flu (Always receives a flu shot annually in November.). Past adverse reactions to the above products included No adverse effect with Covid-19 vaccine, Covid-19 vaccine and Flu. On 23-Sep-2024, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use) .5 milliliter. On 12-Feb-2025, the patient experienced COVID-19 (tested positive with Covid (home test) on 12FEB2025), TASTE DISORDER (Awful taste in the mouth), MALAISE (still feel unwell), EAR PAIN (ears hurt) and CHEST PAIN (chest hurts). At the time of the report, COVID-19 (tested positive with Covid (home test) on 12FEB2025), MALAISE (still feel unwell), EAR PAIN (ears hurt) and CHEST PAIN (chest hurts) was resolving and TASTE DISORDER (Awful taste in the mouth) had resolved. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Feb-2025, SARS-CoV-2 test: (Positive) Covid (home test). On 19-Feb-2025, SARS-CoV-2 test: Negative. For mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use), the reporter did not provide any causality assessments. No concomitant medications were reported. On 08-Mar-2021, The patient received first dose of moderna COVID-19 vaccine (Lot: 036A21A). On 05-Apr-2021, The patient received second dose of moderna COVID-19 vaccine (Lot: 025B21A). On 01-Nov-2021, The patient received 1st booster of moderna COVID-19 vaccine (Lot: 004 F21A). On 02-May-2022, The patient received 2nd booster of moderna COVID-19 vaccine (Lot: 002M21A). On 12-Sep-2022, The patient received Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Lot: AS7143C On 25-Jul-2023, The patient received Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Lot: AS7645B. Patient never had a fever but due to an "Awful taste in the mouth", decided to test for Covid. Patient had an appointment with HCP on Monday i.e., 24-FEB-2025. No vaccines were received in the 4 weeks prior to last vaccine. It was unknown if the patient experienced any additional symptoms/events. No treatment medications were reported. This case was linked to US-MODERNATX, INC.-MOD-2022-660956 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2022-660956:Same patient with different moderna product More
2828887 67 M CA 02/28/2025 COVID19
 MODERNA
Seizure Seizure
seizure; This spontaneous case was reported by a pharmacist and describes the occurrence of SEIZURE ... seizure; This spontaneous case was reported by a pharmacist and describes the occurrence of SEIZURE (seizure) in a 68-year-old male patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis. The patient's past medical history included Falling (history of falling), Major depressive disorder, Metabolic encephalopathy and Unspecified protein-calorie malnutrition. Concurrent medical conditions included Dementia (unspecified dementia), Adult failure to thrive, Bradycardia, Schizophrenia, Epilepsy, Anemia, Hyperlipidemia, Essential hypertension and Generalized osteoarthritis. In October 2024, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use) .5 milliliter. In December 2024, the patient experienced SEIZURE (seizure) (seriousness criterion medically significant). At the time of the report, SEIZURE (seizure) outcome was unknown. For mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use), the reporter considered SEIZURE (seizure) to be related. Patient had no known allergies. All the historical condition was as of 16-May-2024 according to the resident's face sheet. It was unknown if the patient had any additional medical history, concomitant disease or risk factor. Concomitant product use was not provided by the reporter. It was reported that patient was in a skilled nursing facility at the time of vaccination. There were no lab data or results were available. Treatment information was not provided. It was reported that seizure was risk from COVID vaccines.; Reporter's Comments: The medical history of Metabolic encephalopathy, concurrent medical conditions dementia, Schizophrenia and Epilepsy are confounders for the event. In view of the long non-suggestive onset latency the causality of the event was assessed as not related to the vaccine. The benefit -risk relationship of product is not affected by this report. More
2828888 60 M 02/28/2025 COVID19
 MODERNA
Herpes virus infection, Herpes virus test, Respiratory disorder Herpes virus infection, Herpes virus test, Respiratory disorder
Moderna vaccine caused herpes, and respiratory issues / he now has both; Moderna vaccine caused herp... Moderna vaccine caused herpes, and respiratory issues / he now has both; Moderna vaccine caused herpes, and respiratory issues / he now has both; This spontaneous case was reported by a patient and describes the occurrence of HERPES VIRUS INFECTION (Moderna vaccine caused herpes, and respiratory issues / he now has both) and RESPIRATORY DISORDER (Moderna vaccine caused herpes, and respiratory issues / he now has both) in a 60-year-old male patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. No Medical History information was reported. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced HERPES VIRUS INFECTION (Moderna vaccine caused herpes, and respiratory issues / he now has both) and RESPIRATORY DISORDER (Moderna vaccine caused herpes, and respiratory issues / he now has both). At the time of the report, HERPES VIRUS INFECTION (Moderna vaccine caused herpes, and respiratory issues / he now has both) and RESPIRATORY DISORDER (Moderna vaccine caused herpes, and respiratory issues / he now has both) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Herpes virus test: Positive. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. No concomitant medication was reported. Patient had read reports suggesting that the moderna vaccine was linked to herpes and respiratory issues, and he now experiences both conditions. He discovered that moderna planned to release a herpes cure in June 2025, raised questions about accessibility and affordability for average workers, especially since he had limited financial resources. He was inactive sexually for over 20 years, he underwent a physical in 2019 that included herpes testing, which returned negative results. However, after receiving the moderna vaccine and boosters during the covid pandemic, he tested positive for herpes in a 2024 physical, a result he found shocking. Despite retesting twice with the same positive outcome, he felt devastated. Now in his 60s and eager to started dating, he was hesitant to pursue relationships due to the fear of unintentionally transmitting the virus, even with protection. It was unknown if the patient experienced any additional symptoms or events. No treatment medication was reported. More
2828889 M 02/28/2025 COVID19
 PFIZER\BIONTECH
Memory impairment Memory impairment
lost all sense of recognition as to me were we live anything that was familiar to him; This is a spo... lost all sense of recognition as to me were we live anything that was familiar to him; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A male patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), on 24Feb2025 as dose 1, 30 ug single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MEMORY IMPAIRMENT (non-serious) with onset 24Feb2025, outcome "unknown", described as "lost all sense of recognition as to me were we live anything that was familiar to him". No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202500043877 same reporter/event, different patient; More
2828891 82 M MA 02/28/2025 RSV
RSV
RSV
RSV
 UNKNOWN MANUFACTURER
UNKNOWN MANUFACTURER
PFIZER\WYETH
PFIZER\WYETH



Hypoaesthesia, Laboratory test; Hypoaesthesia; Hypoaesthesia, Laboratory test; H... Hypoaesthesia, Laboratory test; Hypoaesthesia; Hypoaesthesia, Laboratory test; Hypoaesthesia More
much like Guillain Barre Syndrome; Numbness in my extremities/Numbness in my feet and hands; This is... much like Guillain Barre Syndrome; Numbness in my extremities/Numbness in my feet and hands; This is a spontaneous report received from a Consumer or other non HCP. An 82-year-old male patient received rsv vaccine prot.subunit pref 2v (RSV VACCINE PROT.SUBUNIT PREF 2V), on 18Feb2025 as dose 1, single (Batch/Lot number: unknown) at the age of 82 years intramuscular (left shoulder) for immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: HYPOAESTHESIA (hospitalization) with onset 21Feb2025 at 06:30, outcome "unknown", described as "Numbness in my extremities/Numbness in my feet and hands"; GUILLAIN-BARRE SYNDROME (hospitalization, medically significant) with onset 21Feb2025 at 06:30, outcome "unknown", described as "much like Guillain Barre Syndrome". The patient was hospitalized for guillain-barre syndrome, hypoaesthesia (start date: 22Feb2025). The patient underwent the following laboratory tests and procedures: Lab work: Unknown results. The information on the batch/lot number for rsv vaccine prot.subunit pref 2v will be requested and submitted if and when received. More
โœ“
2828892 F CA 02/28/2025 PNC20
 PFIZER\WYETH
Arthritis, Mouth swelling, Pain in extremity, Pain in jaw, Peripheral swelling Arthritis, Mouth swelling, Pain in extremity, Pain in jaw, Peripheral swelling
Her arm was very/really sore for many days and swollen at the the same time; It's on the right... Her arm was very/really sore for many days and swollen at the the same time; It's on the right side of mouth where she is having issues, it was swollen; Her jaw hurts a lot.; TMJ joint is inflamed; TMJ joint is inflamed; Her arm was very/really sore for many days and swollen at the the same time; This is a spontaneous report received from a Consumer or other non HCP. A 60-year-old female patient received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), on 22Feb2025 as dose number unknown, single (Batch/Lot number: unknown), in right arm for immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 23Feb2025, outcome "recovered" (26Feb2025), PERIPHERAL SWELLING (non-serious), outcome "recovered" (26Feb2025) and all described as "Her arm was very/really sore for many days and swollen at the the same time"; PAIN IN JAW (non-serious) with onset 23Feb2025, outcome "not recovered", described as "Her jaw hurts a lot."; TEMPOROMANDIBULAR PAIN AND DYSFUNCTION SYNDROME (non-serious), ARTHRITIS (non-serious) all with onset 23Feb2025, outcome "not recovered" and all described as "TMJ joint is inflamed"; MOUTH SWELLING (non-serious), outcome "unknown", described as "It's on the right side of mouth where she is having issues, it was swollen". Therapeutic measures were taken as a result of pain in jaw, temporomandibular pain and dysfunction syndrome, arthritis. Therapeutic measures were not taken as a result of pain in extremity, peripheral swelling. Additional information: TMJ joint is inflamed: She further explained it hurts when drink hot and cold. She cannot pin point a tooth whole, whole side is sore. Patient took Ibuprofen once or twice a day for TMJ joint is inflamed. The patient did not receive any other vaccines within 4 weeks prior to the vaccine(s). The information on the batch/lot number for pneumococcal 20-val conj vac (dipht CRM197 protein) will be requested and submitted if and when received. More
2828893 F LA 02/28/2025 COVID19
 PFIZER\BIONTECH
COVID-19, Drug ineffective COVID-19, Drug ineffective
first time ever getting Covid; first time ever getting Covid; This is a spontaneous report received ... first time ever getting Covid; first time ever getting Covid; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A 62-year-old female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as does 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary series complete.), for Covid-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "first time ever getting Covid". The event "first time ever getting covid" required emergency room visit. Clinical details: the patient stated that out of all the times, this was her first time ever getting Covid, she never had it. She got all her Covid shots. More
2828894 F NC 02/28/2025 COVID19
 PFIZER\BIONTECH
Fatigue, Lichenoid keratosis Fatigue, Lichenoid keratosis
lichenoid dermatitis; long term fatigue; This is a spontaneous report received from a Consumer or ot... lichenoid dermatitis; long term fatigue; This is a spontaneous report received from a Consumer or other non HCP. A 73-year-old female patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "hypothyroidism" (unspecified if ongoing); "depression" (unspecified if ongoing); "Chronic fatigue/long hauler covid" (unspecified if ongoing); "Chronic fatigue/long hauler covid" (unspecified if ongoing); "insomnia" (unspecified if ongoing); "L ventricular regurgitation/coronary artery disease" (unspecified if ongoing); "L ventricular regurgitation/coronary artery disease" (unspecified if ongoing); "mild copd" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE taken for hypothyroidism; WELLBUTRIN taken for depression; TRINTELLIX taken for depression; ADDERALL taken for fatigue, post-acute covid-19 syndrome; CLONAZEPAN taken for insomnia; ASA taken for coronary artery disease, mitral valve incompetence. Past drug history included: Codeine for Drug allergy; Talwin for Drug allergy; Augmentin for Drug allergy; Zpak for Drug allergy; Erythromycin for Drug allergy; Lunesta for Drug allergy; Seroquel for Drug allergy. The following information was reported: LICHENOID KERATOSIS (non-serious), outcome "unknown", described as "lichenoid dermatitis"; FATIGUE (non-serious), outcome "unknown", described as "long term fatigue". The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202500007634 same patient, product, event; different dose; More
2828895 M FL 02/28/2025 FLU3
FLU3
 SEQIRUS, INC.
SEQIRUS, INC.
 946583
946583
Facial paralysis, Gait disturbance, Guillain-Barre syndrome, Paraesthesia, Presy... Facial paralysis, Gait disturbance, Guillain-Barre syndrome, Paraesthesia, Presyncope; Syncope, Walking aid user More
Guillain-Barre Syndrome; Facial paralysis is still pretty significant.; Patient still can't wal... Guillain-Barre Syndrome; Facial paralysis is still pretty significant.; Patient still can't walk without walker; Syncope; Presyncope; Paresthesia; This spontaneous case, initially received on 20-Feb-2025, was reported by a health professional and concerns an adult male patient. Concomitant medication were reported as unknown and patient has no medical history. There was no allergy information reported. There was no product complaint associated with this case. Administration of company suspect drug: On 01-Jan-2025, the patient received Flucelvax (TIV) for Indication not reported, Dose regimen: 0.5 ml, Route of administration: not reported, Anatomical location: not reported, Lot number: 946583. No additional suspect drugs. Adverse reactions/events and outcomes: On 14-Feb-2025, the patient experienced Guillain-Barre Syndrome (Medically Significant, Hospitalized, outcome: Not recovered / Not resolved), Facial paralysis is still pretty significant (Medically Significant, Hospitalized, outcome: Not recovered / Not resolved), Patient still can't walk without walker (Hospitalized, outcome: Not recovered / Not resolved). On an unknown date, the patient experienced Syncope (Medically Significant, outcome: Not Reported), presyncope (outcome: Not Reported), paresthesia (outcome: Not Reported). The following additional adverse events had been identified during post-approval use of FLUCELVAX or FLUCELVAX QUADRIVALENT. Because these events were reported voluntarily from a population of uncertain size, it was not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine. Nervous systems disorders: Syncope, presyncope, paresthesia, Guillain-Barr๏ฟฝ syndrome." Patient received Flucelvax and experienced Guillain-Barr๏ฟฝ Syndrome. Patient still could not walk without walker and facial paralysis was still pretty significant. Patient never experienced an adverse reaction to the vaccine. It was prescribed to patient 5 days of hemoglobulin therapy infusion. Flucelvax (TIV) action taken: Not Applicable Treatment medication: Hemoglobin Reporter's assessment: The reporter assessed the events Guillain-Barre Syndrome, Facial paralysis is still pretty significant, and Patient still can't walk without walker as serious (Hospitalization) and did not provide the causality assessment. The reporter did not provide the seriousness and causality assessment for the rest of the events.; Reporter's Comments: Due to the spontaneous nature of the case, it is considered related for reporting purposes. Causal association could not be completely ruled out in view of insufficient information, hence causality assessed as related.(onset latency/temporality, medical history, concomitant drugs,diagnostic reports). Brighton collaboration criteria assessed as Level 4 (insufficient information to meet any level of certainty) for Guillain Barre Syndrome and facial paralysis . More
โœ“
2828896 83 F 02/28/2025 COVID19
COVID19
UNK
UNK
 UNKNOWN MANUFACTURER
UNKNOWN MANUFACTURER
UNKNOWN MANUFACTURER
UNKNOWN MANUFACTURER
 6024MF020
6024MF020
388489
388489
Acute respiratory failure, Areflexia, CSF glucose, CSF protein, CSF red blood ce... Acute respiratory failure, Areflexia, CSF glucose, CSF protein, CSF red blood cell count; CSF white blood cell count, Guillain-Barre syndrome, Muscular weakness, Quadriplegia, Toxic encephalopathy; Acute respiratory failure, Areflexia, CSF glucose, CSF protein, CSF red blood cell count; CSF white blood cell count, Guillain-Barre syndrome, Muscular weakness, Quadriplegia, Toxic encephalopathy More
Acute respiratory failure; Guillain-Barre syndrome; Acute toxic metabolic encephalopathy; Quadripleg... Acute respiratory failure; Guillain-Barre syndrome; Acute toxic metabolic encephalopathy; Quadriplegia; Areflexia; Muscular weakness; This spontaneous case, initially received on 21-Feb-2025, was reported by a non health professional and concerns an elderly female patient. Drug history included cefaclor (Reaction: allergy), erithromycin (Reaction: allergy). At the time of the event the patient had hypothyroidism, osteoporosis, hypertension, hypercholesterolemia, cerebrovascular small vessel disease, sciatica, osteoarthritis. On an unknown date, the patient had clotting factor transfusion and endotracheal intubation. Concomitant medication: refer to appropriate report section. Administration of company suspect drug: On 03-Dec-2024, the patient received Fluad (TIV) for Drug use for unknown indication, Dose regimen and anatomical location: not reported, Route of administration: Unknown, Lot number: 388489. Non-company suspect drugs: Novavax COVID-19 Vaccine (COVID-19 vaccine prot. subunit (NVX CoV 2373)), Indication: COVID-19 immunisation. Patient received 0.5 ml, intramuscular, anatomical location: not reported on 03-Dec-2024. Adverse reactions/events and outcomes: On 25-Dec-2024, the patient experienced Acute respiratory failure (Medically Significant, Hospitalized, outcome: Unknown), Acute toxic metabolic encephalopathy (Medically Significant, Hospitalized, outcome: Unknown) and Guillain-Barre syndrome (Medically Significant, Hospitalized, outcome: Unknown) Associated symptoms included, Quadriplegia, Muscular weakness, Areflexia. An elderly female with relevant past medical history of hypertension, hyperlipidemia and hypothyroidism presented to an OSH (outside hospital) on 26-Dec-2024 with complaint of significant lower extremity weakness. Patient was found to have AIDP (Acute inflammatory demyelinating polyneuropathy), acute respiratory failure (extubated 05-Jan-2025), and acute toxic metabolic encephalopathy, now sip plasmapheresis (completed on 15-Jan-2025) and cryoprecipitate (16-Jan-2025) now presenting with incomplete tetraplegia with LE (lower extremity) much more affected than UE (upper extremity). Admitted to for AIDP on 17-Jan-2025. AIDP -consistent with GBS, especially given elevated CSF protein, absent DTRs and recent influenza and COVID vaccines about 1 month ago -CSF studies to date reviewed: Protein 124.6, glucose 101 -Lactic acid 2.2 -WBC 1, RBC 1 -Gram stain no organisms, Cx NGTD -VDRL not detected -VZV, HSV, CMV, WNV, enterovirus PCR negative -KOH prep reveals no mycelia or yeast forms; ABF smear negative -Cytology revealed increased white cells with a few neutrophils, lymphocytes and many monocytes -Completed 5 sessions of plasmapheresis last on 15-Jan-2205. Relevant lab tests included: CSF CULTURE NEGATIVE (Result: Negative, Test Date: Unknown), CSF GLUCOSE INCREASED (Result: INCREASED, Test Date: Unknown), CSF LACTATE DECREASED (Result: DECREASED, Test Date: Unknown), CSF PROTEIN INCREASED (Result: INCREASED, Test Date: Unknown), CSF RED BLOOD CELL COUNT POSITIVE (Result: Positive, Test Date: Unknown), CSF WHITE BLOOD CELL COUNT NEGATIVE (Result: Negative, Test Date: Unknown), CYTOLOGY ABNORMAL (Result: ABNORMAL, Test Date: Unknown) (increased white cells with a few neutrophils, lymphocytes and many monocytes), CYTOMEGALO VIRUS TEST NEGATIVE(Result: Negative, Test Date: Unknown), ENTERO VIRUS TEST NEGATIVE (Result: Negative, Test Date: Unknown), GRAM STAIN NEGATIVE (Result: Negative, Test Date: Unknown), HERPES SIMPLEX TEST NEGATIVE (Result: Negative, Test Date: Unknown), MYCOBACTERIUM TEST NEGATIVE (Result: Negative, Test Date: Unknown), POTASSIUM HYDROXIDE PREPARATION NEGATIVE (Result: Negative, Test Date: Unknown), TREPONEMA TEST NEGATIVE ( Result: Negative, Test Date: Unknown), VARJCELLA VIRUS TEST NEGATIVE (Result: Negative, Test Date: Unknown) and WEST NILE VIRUS TEST NEGATIVE (Result: Negative, Test Date: Unknown). At the time of reporting, the event outcome of Acute respiratory failure was Unknown, Areflexia was Unknown, CSF glucose increased was Unknown, CSF red blood cell count positive was Unknown, CSF lactate decreased was Unknown, Guillain-Barre syndrome was Unknown, Quadriplegia was Unknown, CSF protein increased was Unknown, Cytology abnormal was Unknown, Toxic encephalopathy was Unknown and Muscular weakness was Unknown. Fluad (TIV) action taken: Not Applicable Reporter's causality: The reporter did not provide causality assessment and all events considered as serious (Hospitalization and medically significant).; Reporter's Comments: Due to the spontaneous nature of the case, the events are considered related for reporting purposes. Related for Guillain-Barre syndrome due to pharmacological plausibility. Guillain-Barre syndrome and Toxic encephalopathy are assessed as contributing factors for acute respiratory failure. Of note, co-suspect Novavax vaccine is considered as confounder for the events. The case meets Level 4 (due to insufficient information) Brighton Collaboration diagnostic certainty for the event of Guillain-Barre syndrome. More
โœ“
2828902 M 02/28/2025 COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
 PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH








Myocardial infarction, Ventricular fibrillation; Myocardial infarction, Ventricu... Myocardial infarction, Ventricular fibrillation; Myocardial infarction, Ventricular fibrillation; COVID-19, Drug ineffective; Myocardial infarction, Ventricular fibrillation; Myocardial infarction, Ventricular fibrillation; COVID-19, Drug ineffective; Myocardial infarction, Ventricular fibrillation; Myocardial infarction, Ventricular fibrillation; COVID-19, Drug ineffective More
Vfib heart attack; Vfib heart attack; This is a spontaneous report received from a Consumer or other... Vfib heart attack; Vfib heart attack; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A male patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for Covid-19 immunization. The following information was reported: VENTRICULAR FIBRILLATION (death), MYOCARDIAL INFARCTION (death) all with onset Jan2022, outcome "fatal" and all described as "Vfib heart attack". The patient date of death was Jan2022. Reported cause of death: "Vfib heart attack", "heart attack". It was not reported if an autopsy was performed. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.; Sender's Comments: Linked Report(s) : UM-PFIZER INC-PV202500024499 Same patient and suspect product different dose/AE;; Reported Cause(s) of Death: Vfib heart attack; heart attack More
โœ“
2828903 F NV 02/28/2025 COVID19
 PFIZER\BIONTECH
Alopecia Alopecia
The nurse told her she was losing her hair as well; This is a spontaneous report received from a Con... The nurse told her she was losing her hair as well; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A female patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ALOPECIA (non-serious), outcome "not recovered", described as "The nurse told her she was losing her hair as well". Additional information: Reporter stated she was talking to a lady in the store, and they were comparing Pfizer covid vaccine things. She was a nurse and stated that 15,000 people had same reaction as she did with Pfizer Covid vaccine. The nurse told her she was losing her hair as well after the Pfizer Covid vaccine. The lady said she had the same and at least 15,000 had the same reaction she did. The information on the batch/lot number for BNT162b2 omicron (kp.2) will be requested and submitted if and when received. More
2828904 VA 02/28/2025 PNC20
 PFIZER\WYETH
 LK6655
Device breakage Device breakage
one of the 10 vials in the box was cracked; This is a spontaneous report received from an Other HCP ... one of the 10 vials in the box was cracked; This is a spontaneous report received from an Other HCP from product quality group. A patient (age and gender not provided) received pneumococcal 20- valent conjugate vaccine (diphtheria CRM197 protein) (PREVNAR 20), as dose number unknown., single (Lot number: LK6655, Expiration Date: 30Jun2026) for immunisation, Device Lot Number: LK6655, Device Expiration Date: 30Jun2026. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PRODUCT PHYSICAL ISSUE (non-serious), outcome "unknown", described as "one of the 10 vials in the box was cracked". The reporter considered "one of the 10 vials in the box was cracked" not related to pneumococcal 20- valent conjugate vaccine (diphtheria CRM197 protein). Causality for "one of the 10 vials in the box was cracked" was determined associated to device constituent of pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 protein) (malfunction). More
2828906 34 F MA 02/28/2025 FLU3
 GLAXOSMITHKLINE BIOLOGICALS
 53Ky2
CSF test, Headache, Imaging procedure, Laboratory test, Neurodegenerative disord... CSF test, Headache, Imaging procedure, Laboratory test, Neurodegenerative disorder More
Vaccine given on 11/1/24. Headache lasting 5 days that started on 11/4/24. On 11/15 started with neu... Vaccine given on 11/1/24. Headache lasting 5 days that started on 11/4/24. On 11/15 started with neurologic findings that would lead to diagnosis of autoimmune cerebellar degeneration. More
โœ“ โœ“
2828907 64 F 02/28/2025 HEPAB
 GLAXOSMITHKLINE BIOLOGICALS
 m4b34
Inappropriate schedule of product administration, No adverse event Inappropriate schedule of product administration, No adverse event
No adverse effect 3rd dose of twinrix gives less than 6 months from first (shot given 2/26/25 instea... No adverse effect 3rd dose of twinrix gives less than 6 months from first (shot given 2/26/25 instead of 3/13/2025) More
2828908 53 F FL 02/28/2025 UNK
 UNKNOWN MANUFACTURER
Injection site erythema, Injection site swelling Injection site erythema, Injection site swelling
Red localized swelling at administration site Red localized swelling at administration site
2828919 57 F TX 02/28/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 93kk4
Unevaluable event Unevaluable event
Patient stated she experience 100 degree fever. Patient stated she experience 100 degree fever.
2828920 57 M NV 02/28/2025 PNC20
 PFIZER\WYETH
 LJ5284
Injection site rash Injection site rash
LITTLE RASH AT THE INJECTION SITE WITH NO SWOLLEN LITTLE RASH AT THE INJECTION SITE WITH NO SWOLLEN
2828921 8 F CA 02/28/2025 HEP
HEP
IPV
IPV
MMRV
MMRV
TDAP
TDAP
 MERCK & CO. INC.
MERCK & CO. INC.
SANOFI PASTEUR
SANOFI PASTEUR
MERCK & CO. INC.
MERCK & CO. INC.
GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS







Cough, Immediate post-injection reaction, Immune thrombocytopenia, Immunoglobuli... Cough, Immediate post-injection reaction, Immune thrombocytopenia, Immunoglobulin therapy, Platelet count decreased; Pyrexia, Respiratory tract congestion; Cough, Immediate post-injection reaction, Immune thrombocytopenia, Immunoglobulin therapy, Platelet count decreased; Pyrexia, Respiratory tract congestion; Cough, Immediate post-injection reaction, Immune thrombocytopenia, Immunoglobulin therapy, Platelet count decreased; Pyrexia, Respiratory tract congestion; Cough, Immediate post-injection reaction, Immune thrombocytopenia, Immunoglobulin therapy, Platelet count decreased; Pyrexia, Respiratory tract congestion More
Immune Thrombocytopenia requiring hospitalization and IVIG infusion Immune Thrombocytopenia requiring hospitalization and IVIG infusion
โœ“
2828922 65 F WA 02/28/2025 MMRV
 MERCK & CO. INC.
 y012341
No adverse event, Product administered to patient of inappropriate age No adverse event, Product administered to patient of inappropriate age
No symptoms, patient was notified, provider was notified No symptoms, patient was notified, provider was notified
2828923 4 M 02/28/2025 MMRV
 MERCK & CO. INC.
Pyrexia, Skin reaction Pyrexia, Skin reaction
local cutaneous reaction, fever. local cutaneous reaction, fever.
2829021 53 F CT 02/28/2025 COVID19
COVID19
COVID19
 PFIZER\BIONTECH
PFIZER\BIONTECH
PFIZER\BIONTECH
 EJ1685
N/A
N/A
Alopecia, Chemotherapy, Colorectal cancer stage IV, Death, Hair growth abnormal;... Alopecia, Chemotherapy, Colorectal cancer stage IV, Death, Hair growth abnormal; Alopecia, Chemotherapy, Colorectal cancer stage IV, Death, Hair growth abnormal; Alopecia, Chemotherapy, Colorectal cancer stage IV, Death, Hair growth abnormal More
Online report of premature death for a health care worker, a mid-50's female. Victim was diagno... Online report of premature death for a health care worker, a mid-50's female. Victim was diagnosed with stage 4 colon cancer in late May 2022, exact date unknown. DOSE1 date 12/23/20 LOT# EJ1685, DOSE2 date UNK, LOT# UNK, DOSE3 date 10/03/2021. LOT# UNK. Online report states victim died at home surrounded by family. Online photos imply victim was injected at work, a facility. Victim went through cycles of hair loss and growth. By 09/22 she had undergone her 8th chemo administered by Dr. . Victim wore masks in occupational and non-occupational settings for 3+ years. Victim likely received medical care or had any hospital stay at Hospital More
โœ“ โœ“
2829022 79 F WI 02/28/2025 PNC21
 MERCK & CO. INC.
Injection site erythema, Injection site pruritus, Injection site swelling Injection site erythema, Injection site pruritus, Injection site swelling
Started with red circle around inj. site, itchy, redness and slight swelling on upper arm. After 24 ... Started with red circle around inj. site, itchy, redness and slight swelling on upper arm. After 24 hours, lasted 72 hours. Relieved with BENADRYL, resolved. More
2829023 1 M NY 02/28/2025 MMR
PNC20
VARCEL
 MERCK & CO. INC.
PFIZER\WYETH
MERCK & CO. INC.
 Y005808
LG5578
Y014939
Injection site discolouration, Injection site induration; Injection site discolo... Injection site discolouration, Injection site induration; Injection site discolouration, Injection site induration; Injection site discolouration, Injection site induration More
~ 1 1/2" x 3" pink area on deltoid, slight firmness right around injection site. No tender... ~ 1 1/2" x 3" pink area on deltoid, slight firmness right around injection site. No tenderness, no swelling or induration. More
2828495 F MN 02/27/2025 HPV9
 MERCK & CO. INC.
 Y007991
Exposure during pregnancy, Pregnancy test positive Exposure during pregnancy, Pregnancy test positive
no adverse event; vaccine exposure during pregnancy; This prospective spontaneous report has been re... no adverse event; vaccine exposure during pregnancy; This prospective spontaneous report has been received from a health professional regarding a 31-year-old female patient. The patient's medical history included rash due to handling bleach. Information regarding concurrent conditions and concomitant therapies was not reported. On 08-JAN-2025, the patient received HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) injection for prophylaxis , lot number Y007991 which has been verified to be valid, expiration date reported and validated as 18-JUN-2026. (strength, dose, scheme, route of administration, and anatomical site not reported) On 12-NOV-2024, the patient's pregnancy test resulted negative. On an unknown date, the caller stated during ultrasound, patient was about 6 weeks and 3 days pregnant when she received vaccine (conflicting information, the reporter stated the patient was "unknowingly pregnant" when she received the vaccine) (vaccination exposure during pregnancy). On 28-JAN-2025, the patient's pregnancy test was positive. No additional information provided, no adverse event. The pregnancy and fetal outcome was unknown. More
2828496 FL 02/27/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Rash Rash
rash on face; This non-serious case was reported by a consumer via call center representative and de... rash on face; This non-serious case was reported by a consumer via call center representative and described the occurrence of rash in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced rash (Verbatim: rash on face). The outcome of the rash was not reported. It was unknown if the reporter considered the rash to be related to Shingrix. It was unknown if the company considered the rash to be related to Shingrix. Additional Information: GSK receipt date: 13-FEB-2025 The reporter reported that the patient had recived Shingrix vaccine and experienced rash. The reporter had a question about Shingrix vaccine could it cause a rash on face and how long to go away. More
2828497 9 M NV 02/27/2025 FLU3
 GLAXOSMITHKLINE BIOLOGICALS
Extra dose administered, Incorrect dose administered Extra dose administered, Incorrect dose administered
9-year-old male patient was accidentally given two doses of Flulaval; should have received Flulaval ... 9-year-old male patient was accidentally given two doses of Flulaval; should have received Flulaval and Gardasil/9-year-old male patient was accidentally given two doses of Flulaval; This non-serious case was reported by a other health professional via call center representative and described the occurrence of accidental overdose in a 9-year-old male patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) for prophylaxis. Co-suspect products included HPV VACCINE VLP RL1 4V (YEAST) (GARDASIL) for prophylaxis. Concomitant products included INFLUENZA VACCINE INACT SPLIT 3V (FLULAVAL). On 30-JAN-2025 17:10, the patient received FluLaval 2024-2025 season (right deltoid). On an unknown date, the patient received GARDASIL. On 30-JAN-2025 17:10, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced accidental overdose (Verbatim: 9-year-old male patient was accidentally given two doses of Flulaval) and wrong vaccine administered (Verbatim: should have received Flulaval and Gardasil/9-year-old male patient was accidentally given two doses of Flulaval). The outcome of the accidental overdose and wrong vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 30-JAN-2025 The patient was accidentally given two doses of Flulaval, one in the Left Deltoid, and one in the Right Deltoid. The patient should have received Flulaval and Gardasil, and the patient's sibling was also going to get the flu shot, but she somehow put everything on one tray, and the 9-year-old got 2 doses of flu, which led to accidental overdose and wrong vaccine administered. No further details were provided. The reporter consented to follow up. More
2828515 25 AZ 02/27/2025 UNK
 UNKNOWN MANUFACTURER
Chills, Pyrexia Chills, Pyrexia
High fever, shivers High fever, shivers
2828516 36 F CA 02/27/2025 RSV
 PFIZER\WYETH
 KC7884
Exposure during pregnancy, Premature delivery, Premature labour Exposure during pregnancy, Premature delivery, Premature labour
Pre-term labor. Pregnancy was otherwise uncomplicated. Estimated date of delivery was 1/4/25. Birth ... Pre-term labor. Pregnancy was otherwise uncomplicated. Estimated date of delivery was 1/4/25. Birth weight was 5 lbs 5 oz More
โœ“
2828517 29 F NC 02/27/2025 COVID19
 PFIZER\BIONTECH
Exposure during pregnancy, Foetal non-stress test normal, Uterine contractions d... Exposure during pregnancy, Foetal non-stress test normal, Uterine contractions during pregnancy More
False labor contractions- due date 3/12/25 False labor contractions- due date 3/12/25
2828520 02/27/2025 VARZOS
 UNKNOWN MANUFACTURER
 UNK
Dizziness, Syncope Dizziness, Syncope
Fainted; Dizzy; This serious case was reported by a consumer via interactive digital media and descr... Fainted; Dizzy; This serious case was reported by a consumer via interactive digital media and described the occurrence of fainting in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On 14-FEB-2025, the patient received the 1st dose of Shingles vaccine. In FEB-2025, an unknown time after receiving Shingles vaccine, the patient experienced fainting (Verbatim: Fainted) (serious criteria GSK medically significant) and dizziness (Verbatim: Dizzy). The outcome of the fainting was resolved and the outcome of the dizziness was not resolved. It was unknown if the reporter considered the fainting and dizziness to be related to Shingles vaccine. The company considered the fainting and dizziness to be unrelated to Shingles vaccine. Additional Information: GSK receipt Date: 15-FEB-2025 This case was reported by a patient via interactive digital media. The patient received shingles vaccine a day before reporting . Now, the patient was extremely dizzy and fainted once.; Sender's Comments: Syncope and Dizziness are unlisted events which are considered unrelated to GSK Shingles vaccine. More
2828521 F 02/27/2025 VARZOS
VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS
 UNK
UNK
Herpes zoster, Vaccination failure; Herpes zoster, Vaccination failure Herpes zoster, Vaccination failure; Herpes zoster, Vaccination failure
Suspected vaccination failure; shingles; This serious case was reported by a other health profession... Suspected vaccination failure; shingles; This serious case was reported by a other health professional and described the occurrence of vaccination failure in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: shingles). The outcome of the vaccination failure was not reported and the outcome of the shingles was resolved. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix. The company considered the vaccination failure to be unrelated to Shingrix and Shingrix. It was unknown if the company considered the shingles to be related to Shingrix and Shingrix. Additional Information: GSK Receipt Date: 12-FEB-2025 Patient received 2 doses of Shingrix and developed shingles. Patient was recovered. The symptoms were treated. This case was considered as suspected vaccination failure as details regarding time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding time to onset and laboratory confirmation of disease) is considered unrelated to GSK vaccine Shingrix (Dose 1 and Dose 2). More
2828522 M 02/27/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Incomplete course of vaccination Incomplete course of vaccination
never received his second; This non-serious case was reported by a consumer via call center represen... never received his second; This non-serious case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine in 2023). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: never received his second ). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 25-FEB-2025 The reporter reported that patient stated that he received his first dose of Shingrix in 2023 and never received his second because he moved. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. More
2828523 02/27/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Skin reaction Skin reaction
Skin reaction; This non-serious case was reported by a consumer via interactive digital media and de... Skin reaction; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of skin reaction in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced skin reaction (Verbatim: Skin reaction). The outcome of the skin reaction was not reported. It was unknown if the reporter considered the skin reaction to be related to Shingrix. It was unknown if the company considered the skin reaction to be related to Shingrix. Additional Information: GSK Receipt Date: 10-FEB-2025 The patient self reported this case for himself/herself This case was reported by a patient via (Shingrix GSK Chatbot) interactive digital media. More
2828524 58 F IL 02/27/2025 VARZOS
VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS

Chills, Headache, Nausea, Pain, Pyrexia; Swelling, Tenderness Chills, Headache, Nausea, Pain, Pyrexia; Swelling, Tenderness
selling in her neck; tender to touch; States there are no visual signs of bruising it just feels lik... selling in her neck; tender to touch; States there are no visual signs of bruising it just feels like bruising; she developed a headache; nausea; she had chills; fever; aches and pains; This non-serious case was reported by a consumer via call center representative and described the occurrence of chills in a 58-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 04-FEB-2025, the patient received the 1st dose of Shingrix (intramuscular, left deltoid) .5 ml. On 04-FEB-2025, 3 hrs after receiving Shingrix, the patient experienced chills (Verbatim: she had chills), fever (Verbatim: fever) and pain (Verbatim: aches and pains). On 05-FEB-2025, the patient experienced headache (Verbatim: she developed a headache) and nausea (Verbatim: nausea). On 06-FEB-2025, the patient experienced neck swelling (Verbatim: selling in her neck), tenderness (Verbatim: tender to touch) and contusion (Verbatim: States there are no visual signs of bruising it just feels like bruising). The outcome of the chills, fever, pain and headache were resolved and the outcome of the nausea and neck swelling were not resolved and the outcome of the tenderness and contusion were not reported. It was unknown if the reporter considered the chills, fever, pain, headache, nausea, neck swelling, tenderness and contusion to be related to Shingrix. It was unknown if the company considered the chills, fever, pain, headache, nausea, neck swelling, tenderness and contusion to be related to Shingrix. Additional Information: GSK receipt date: 06-FEB-2025 The reporter was the patient who received the first dose of Shingrix vaccine series in her left deltoid. The vaccine was administered at the pharmacy. The reporter stated she had experienced chills, fever, aches, and pains 3 hours after receiving vaccine and symptoms have resolved. Also, stated she developed a headache and nausea 1 day after receiving the vaccine. The headache had resolved but the nausea still remains. The reporter mentioned that 2 days after receiving the vaccine she noticed swelling in her left neck that was tender to touch and feels like bruising. The reporter stated there were no visual signs of bruising it just feels like bruising. The selling in her neck still remains. The patient did not have a lot number or number of vaccine on the papers she received from the pharmacy. More
2828525 M FL 02/27/2025 DTAP
 GLAXOSMITHKLINE BIOLOGICALS
 TX77L
Product administered to patient of inappropriate age, Wrong product administered Product administered to patient of inappropriate age, Wrong product administered
16 day old receiving a infanrix vaccine; Administered Infanrix instead of hepatitis B vaccine; This ... 16 day old receiving a infanrix vaccine; Administered Infanrix instead of hepatitis B vaccine; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 16-day-old male patient who received DTPa (Infanrix) (batch number TX77L, expiry date 01-DEC-2025) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. On 21-FEB-2025, the patient received Infanrix. On an unknown date, the patient received Engerix B. On 21-FEB-2025, an unknown time after receiving Infanrix and not applicable after receiving Engerix B, the patient experienced inappropriate age at vaccine administration (Verbatim: 16 day old receiving a infanrix vaccine) and wrong vaccine administered (Verbatim: Administered Infanrix instead of hepatitis B vaccine). The outcome of the inappropriate age at vaccine administration and wrong vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 21-FEB-2025 Other HCP started a 16 day old receiving a Infanrix vaccine. According to reporter, the dose was administered earlier that day. Reporter had a 16 days old baby that received Infanrix instead of the Hepatitis B, Engerix-B, which led to wrong vaccine administered. Reporter need to know what they need to do for this child. 16 day old receiving a Infanrix vaccine, which led to inappropriate age at vaccine administration. More
2828527 48 F FL 02/27/2025 COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
COVID19
 MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
MODERNA
 039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
027C21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
039B21A
Abdominal pain upper, Agitation, Aphasia, Arthritis, Blister; Blood pressure flu... Abdominal pain upper, Agitation, Aphasia, Arthritis, Blister; Blood pressure fluctuation, Blood test, Brain fog, Chronic active Epstein-Barr virus infection, Chronic fatigue syndrome; Colonoscopy, Computerised tomogram head, Depression, Disturbance in attention, Dizziness; Dysgraphia, Echocardiogram, Electrocardiogram ambulatory, Endoscopy, Epstein-Barr virus test; Exercise tolerance decreased, Fatigue, Gastrointestinal disorder, Herpes zoster, Insomnia; Irritable bowel syndrome, Magnetic resonance imaging head, Malaise, Muscle atrophy, Myositis; Night sweats, Onychomadesis, Oral herpes, Pain in extremity, Photophobia; Pyrexia, Rash, Rash erythematous, Scan with contrast, Temperature regulation disorder; Trigeminal nerve disorder, Urinary incontinence, Visual impairment; Alpha 1 globulin, Alpha 2 globulin, Basophil count, Basophil percentage, Beta globulin; Bipolar disorder, Blood albumin, Blood pressure measurement, Blood test, Chronic fatigue syndrome; Constipation, Electrocardiogram ambulatory, Endoscopy, Eosinophil count, Eosinophil percentage; Epstein-Barr virus antibody, Epstein-Barr virus infection, Fibromyalgia, Haematocrit, Haemoglobin; Herpes zoster, Hypertension, Immature granulocyte count, Immunoglobulins, Infectious mononucleosis; Irritable bowel syndrome, Joint noise, Loss of libido, Lymphocyte count, Lymphocyte percentage; Mean cell haemoglobin, Mean cell haemoglobin concentration, Mean cell volume, Mean platelet volume, Monocyte count; Monocyte percentage, Muscle atrophy, Neutrophil count, Neutrophil percentage, Nucleated red cells; Onychomadesis, Pain, Pain in extremity, Palpitations, Petechiae; Platelet count, Protein total, Red blood cell count, Red cell distribution width, Rheumatoid arthritis; Transient ischaemic attack, Trigeminal neuralgia, Weight, White blood cell count; Abdominal pain upper, Agitation, Aphasia, Arthritis, Blister; Blood pressure fluctuation, Blood test, Brain fog, Chronic active Epstein-Barr virus infection, Chronic fatigue syndrome; Colonoscopy, Computerised tomogram head, Depression, Disturbance in attention, Dizziness; Dysgraphia, Echocardiogram, Electrocardiogram ambulatory, Endoscopy, Epstein-Barr virus test; Exercise tolerance decreased, Fatigue, Gastrointestinal disorder, Herpes zoster, Insomnia; Irritable bowel syndrome, Magnetic resonance imaging head, Malaise, Muscle atrophy, Myositis; Night sweats, Onychomadesis, Oral herpes, Pain in extremity, Photophobia; Pyrexia, Rash, Rash erythematous, Scan with contrast, Temperature regulation disorder; Trigeminal nerve disorder, Urinary incontinence, Visual impairment; Alpha 1 globulin, Alpha 2 globulin, Basophil count, Basophil percentage, Beta globulin; Bipolar disorder, Blood albumin, Blood pressure measurement, Blood test, Chronic fatigue syndrome; Constipation, Electrocardiogram ambulatory, Endoscopy, Eosinophil count, Eosinophil percentage; Epstein-Barr virus antibody, Epstein-Barr virus infection, Fibromyalgia, Haematocrit, Haemoglobin; Herpes zoster, Hypertension, Immature granulocyte count, Immunoglobulins, Infectious mononucleosis; Irritable bowel syndrome, Joint noise, Loss of libido, Lymphocyte count, Lymphocyte percentage; Mean cell haemoglobin, Mean cell haemoglobin concentration, Mean cell volume, Mean platelet volume, Monocyte count; Monocyte percentage, Muscle atrophy, Neutrophil count, Neutrophil percentage, Nucleated red cells; Onychomadesis, Pain, Pain in extremity, Palpitations, Petechiae; Platelet count, Protein total, Red blood cell count, Red cell distribution width, Rheumatoid arthritis; Transient ischaemic attack, Trigeminal neuralgia, Weight, White blood cell count; Abdominal pain upper, Agitation, Aphasia, Arthritis, Blister; Blood pressure fluctuation, Blood test, Brain fog, Chronic active Epstein-Barr virus infection, Chronic fatigue syndrome; Colonoscopy, Computerised tomogram head, Depression, Disturbance in attention, Dizziness; Dysgraphia, Echocardiogram, Electrocardiogram ambulatory, Endoscopy, Epstein-Barr virus test; Exercise tolerance decreased, Fatigue, Gastrointestinal disorder, Herpes zoster, Insomnia; Irritable bowel syndrome, Magnetic resonance imaging head, Malaise, Muscle atrophy, Myositis; Night sweats, Onychomadesis, Oral herpes, Pain in extremity, Photophobia; Pyrexia, Rash, Rash erythematous, Scan with contrast, Temperature regulation disorder; Trigeminal nerve disorder, Urinary incontinence, Visual impairment; Alpha 1 globulin, Alpha 2 globulin, Basophil count, Basophil percentage, Beta globulin; Bipolar disorder, Blood albumin, Blood pressure measurement, Blood test, Chronic fatigue syndrome; Constipation, Electrocardiogram ambulatory, Endoscopy, Eosinophil count, Eosinophil percentage; Epstein-Barr virus antibody, Epstein-Barr virus infection, Fibromyalgia, Haematocrit, Haemoglobin; Herpes zoster, Hypertension, Immature granulocyte count, Immunoglobulins, Infectious mononucleosis; Irritable bowel syndrome, Joint noise, Loss of libido, Lymphocyte count, Lymphocyte percentage; Mean cell haemoglobin, Mean cell haemoglobin concentration, Mean cell volume, Mean platelet volume, Monocyte count; Monocyte percentage, Muscle atrophy, Neutrophil count, Neutrophil percentage, Nucleated red cells; Onychomadesis, Pain, Pain in extremity, Palpitations, Petechiae; Platelet count, Protein total, Red blood cell count, Red cell distribution width, Rheumatoid arthritis; Transient ischaemic attack, Trigeminal neuralgia, Weight, White blood cell count More
Since receiving the Moderna vaccine I have been diagnosed with chronic EBV, CFS/ME, uncontrollable B... Since receiving the Moderna vaccine I have been diagnosed with chronic EBV, CFS/ME, uncontrollable BP, admitted in hospital under stroke alert. Depression.Unexplained fever. Often feel malaise. Severe inflammation in joints & muscles. Loss of muscle mass. Agitation, depression. Difficulty regulating body temperature.Trigeminal nerve flareup. Stomach & digestive issues, IBS. Worsening vision & sensitivity to light. Extreme fatigue, foggy brain & trouble concentrating. My handwriting has gotten worse. Please see additional symptoms below: At times, difficulty articulating sentences. Insomnia. Unregulated body temperature. Uncontrollable sweating at night. Admitted to the hospital under stroke watch. Stomach pain with digestive issues. Red rash on lower arms & legs. Rash on the right side of the face, more so on the right side. Excruciating thigh pain. Extreme exhaustion after low exercise or daily activities. EBV flareups will start in my face, work their way down my body, through my digestive tract, down my leg, and come out through my toe, where the toe will blister, and eventually, the nail will fall off. I have all the documentation & dates of "episodes." With EBV since Moderna, I am constantly in a cold sore breakout throughout my body. The scariest episode was when I showed one of my listings, and the seller was home by the grace of God. I got a head rush like I have never had in my life. It would not go away. My seller sat me down and gave me water & cold compress. Asked if she should call EMS. I said no, I don't need that bill.... I went to the ER the next morning, and my BP was at stroke levels, and that is when I was admitted. I can't imagine what my blood pressure was during the showing. I have seen my: A primary care provider on more than one occasion. She ran the EBV test and other bloodwork. That doctor left another doctor took her place and he said he won't run the EBV test again because once you have it, you always have it. I've paid out of pocket and have had myself tested, keeping an eye on my EBV load Gastroenterologist twice in the past few years who has performed endoscopy & colonoscopy to try and figure out if something was going on inside The podiatrist showing her blistered toes Rheumatoid Arthritis doctor who could not understand why my PCP referred me to her A Psychiatrist who tried to put me on antidepressant Cardiologist for heart ultrasound & to wear a halter for 5 days (waiting to see if they call me to let me know results because they never scheduled a follow-up appointment with me. Neurologist 1 to rule out MS Neurologist 2 to rule out MS again & to go over mini stroke Urologist 1 to go over incontinent issues with no resolve Urologist 2 to go over incontinent issues again with no resolve I have an appointment with an infectious disease doctor on March 3, 2025 More
โœ“ โœ“
2828528 0.33 F CT 02/27/2025 DTPPVHBHPB
PNC20
RV5
 MSP VACCINE COMPANY
PFIZER\WYETH
MERCK & CO. INC.
 U7921AA
LC5483
2081735
Infant irritability, Pyrexia; Infant irritability, Pyrexia; Infant irritability,... Infant irritability, Pyrexia; Infant irritability, Pyrexia; Infant irritability, Pyrexia More
Fuzziness and low grade fever. Fuzziness and low grade fever.
2828564 75 F 02/27/2025 COVID19
 MODERNA
 8081561
Expired product administered Expired product administered
Vaccine was given after the BUD - pt will be revaccinated Vaccine was given after the BUD - pt will be revaccinated
2828565 76 F 02/27/2025 COVID19
 MODERNA
 8081561
Expired product administered Expired product administered
Vaccine was given after the BUD - pt will be revaccinated Vaccine was given after the BUD - pt will be revaccinated
2828566 73 F 02/27/2025 COVID19
 MODERNA
 8081561
Expired product administered Expired product administered
Vaccine was given after the BUD - pt will be revaccinated Vaccine was given after the BUD - pt will be revaccinated
2828567 73 M 02/27/2025 COVID19
 MODERNA
 8081561
Expired product administered Expired product administered
Vaccine was given after the BUD - pt will be revaccinated Vaccine was given after the BUD - pt will be revaccinated
2828568 78 M 02/27/2025 COVID19
 MODERNA
 8081561
Expired product administered Expired product administered
Vaccine was given after the BUD - pt will be revaccinated Vaccine was given after the BUD - pt will be revaccinated
๐Ÿ“‹ Privacy Policy & Data Disclaimer